Dataset on insight into inhibition capacity of cyclic tetra-amino acid based compounds as efficient crystal structure of human insulin-degrading enzyme inhibitors

Abstract

) proved to possess greater potential to inhibit human insulin-degrading enzyme (2WBY) than other examined compounds and the reference compound (Metformin). The pharmacokinetic evaluation of compound with highest binding affinity and reference compound were executed and reported. Also, other activity of the lead compound were explored using SwissTargetPrediction software and the outcome were observed and reported.